|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
37,506 |
$2,201,977.26 |
7.28% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
9,416 |
$2,142,140.00 |
7.08% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
18,893 |
$2,114,126.70 |
6.99% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
10,080 |
$2,002,996.80 |
6.62% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,224 |
$1,965,927.04 |
6.50% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
42,301 |
$1,142,127.00 |
3.78% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
78,341 |
$1,142,995.19 |
3.78% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
6,098 |
$1,124,349.24 |
3.72% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,496 |
$1,124,348.72 |
3.72% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
8,922 |
$1,042,714.14 |
3.45% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
3,013 |
$1,038,129.15 |
3.43% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
7,852 |
$1,023,900.80 |
3.39% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
5,102 |
$1,019,634.70 |
3.37% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,354 |
$1,012,902.66 |
3.35% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,726 |
$978,918.16 |
3.24% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,544 |
$696,466.88 |
2.30% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
7,246 |
$685,833.90 |
2.27% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
3,872 |
$495,151.36 |
1.64% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
10,884 |
$489,126.96 |
1.62% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
5,770 |
$393,687.10 |
1.30% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,252 |
$382,389.60 |
1.26% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
916 |
$376,054.64 |
1.24% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
6,690 |
$355,774.20 |
1.18% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
2,785 |
$355,588.80 |
1.18% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,299 |
$346,342.64 |
1.15% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
8,873 |
$295,559.63 |
0.98% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
11,568 |
$263,172.00 |
0.87% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
3,741 |
$260,635.47 |
0.86% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
5,400 |
$218,700.00 |
0.72% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,428 |
$208,902.32 |
0.69% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
2,765 |
$204,361.15 |
0.68% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
7,898 |
$201,399.00 |
0.67% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,346 |
$195,770.52 |
0.65% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
6,970 |
$190,768.90 |
0.63% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
811 |
$187,559.97 |
0.62% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,747 |
$174,700.00 |
0.58% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
13,748 |
$172,124.96 |
0.57% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
583 |
$158,879.16 |
0.53% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,743 |
$159,467.07 |
0.53% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
6,979 |
$154,096.32 |
0.51% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,713 |
$152,302.83 |
0.50% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
3,003 |
$152,342.19 |
0.50% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
5,559 |
$152,372.19 |
0.50% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
483 |
$147,575.82 |
0.49% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,761 |
$149,526.51 |
0.49% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
6,550 |
$143,838.00 |
0.48% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
1,982 |
$145,221.14 |
0.48% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
2,939 |
$146,244.64 |
0.48% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
5,964 |
$138,722.64 |
0.46% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,130 |
$130,888.50 |
0.43% |
| US Dollar |
$USD |
|
Other |
84,546 |
$84,545.70 |
0.28% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|